Head and neck squamous cell carcinoma (HNSCC) arises principally from the mucosal squamous epithelium of the oral cavity, pharynx and larynx. Standard care is multimodal. The review authors reported that neoadjuvant therapy is deployed to downstage the primary tumour, to target occult micrometastatic disease, and to improve locoregional control prior to definitive surgery or radiotherapy. Organ preservation is emphasized as a practical clinical objective when selecting preoperative systemic strategies. The abstract framed these aims as the core rationale for adopting neoadjuvant approaches in patients with locally advanced disease.
Clinicians often use combined cytotoxic regimens as the contemporary neoadjuvant backbone. The review identified taxane, platinum and 5‑fluorouracil as the common components of induction chemotherapy that are integrated with radiotherapy in current practice. The study team described this triplet approach as a prevailing clinical strategy to achieve tumour shrinkage before definitive local therapy. The abstract did not provide regimen doses, cycle numbers, or comparative outcome data for these induction schedules; those specifics were not reported in the source summary.
For patients with pharyngeal or laryngeal disease receiving definitive concurrent chemoradiotherapy, platinum is a standard radiosensitiser. The authors noted an important clinical alternative for patients who are HPV-negative but medically unfit for platinum: the epidermal growth factor receptor-directed monoclonal antibody cetuximab administered concomitantly with radiotherapy. The review abstract indicated this approach as an established option, but it did not list eligibility criteria, toxicity profiles, or comparative efficacy metrics in the abstract itself.
Immune checkpoint inhibitors (ICIs) have already redefined systemic therapy for recurrent and metastatic HNSCC, according to the authors. They reported durable responses and a survival benefit in that disease setting. Building on that systemic experience, early-phase trials have explored the feasibility and efficacy of incorporating ICIs into neoadjuvant protocols for locally advanced disease. The review emphasized these immunotherapy-based paradigms as emerging strategies aimed at improving both oncological and functional outcomes. The abstract did not specify which checkpoint targets, agents, combinations or trial endpoints were evaluated in those early-phase studies.
The authors reported that roughly 65–70% of patients present with stage III–IVA locally advanced disease. This high proportion creates therapeutic challenges and is linked to a pronounced deterioration in quality of life for many patients. That clinical context — advanced stage at presentation combined with potential functional loss from treatment — is presented as a principal motivator for pursuing neoadjuvant strategies that might permit organ preservation or reduce the extent of definitive surgery or radiotherapy.
The abstract synthesizes evolving concepts but does not include granular trial-level data. The review did not report specific dosing regimens, numerical response rates, sample sizes, p-values, or formal trial endpoints in the abstract text. Investigators reported early-phase exploration of ICIs in the neoadjuvant setting, yet the abstract omits details on safety signals, pathological response rates, or long-term survival outcomes. Those omissions limit the ability to assess comparative benefit and to derive practice-changing conclusions directly from the abstract alone. Readers will need the full review or individual trial publications for regimen specifics, toxicity profiles, and validated efficacy endpoints.
Limitations and immediate open questions documented in the source
The review abstract serves as a narrative overview. As such, it summarizes therapeutic evolution and emerging immunotherapy-based paradigms but does not present primary data. The most direct unanswered questions—left unaddressed in the abstract—are which neoadjuvant combinations (including specific ICIs) will produce reproducible pathological responses, how neoadjuvant toxicity will affect surgical fitness and functional outcomes, and which predictive biomarkers should guide patient selection. The review indicates these are active areas of investigation but does not provide trial-level evidence in the abstract to resolve them.